TY  - JOUR
AU  - Zrnić-Ćirić, Milica
AU  - Kotur-Stevuljević, Jelena
AU  - Stanković, Ivan
AU  - Đorđević, Brižita
AU  - Baralić, Ivana
AU  - Ostojić, Miodrag
PY  - 2023
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/4398
AB  - Background: The uneven lipid-lowering statin effects and
statin intolerance raise interest regarding the involvement
of coadministration of statins and dietary supplements.
This study aimed to evaluate the effects of octacosanol
supplementation on markers of redox status in cardiovascular patients on chronic atorvastatin therapy.
Methods: A double-blind, randomized, placebo-controlled,
single-centre study was conducted. Redox status home-
ostasis parameters  i.e., advanced oxidation protein products (AOPP), pro-oxidant-antioxidant balance (PAB), total
oxidant status (TOS), total antioxidant status (TAS), superoxide dismutase activity (SOD), total protein sulfhydryl (SH-
groups), and paraoxonase 1 (PON1) activity  were
assessed in 81 patients. According to favorable changes in
lipid profile, patients were classified into two groups:
responders (n = 35) and non-responders (n = 46), and
followed for 13 weeks. A principal component analysis
(PCA) was applied to explore the effect of octacosanol supplementation and the relationship between investigated
parameters as predictors of responders’ and non-responders’ status.
Results: Significant decrease in Oxy-score value was found
at the endpoint compared to baseline in responders’ group (21.0 (13.4–25.5) versus 15.1 (12.4–18.0); P < 0.01).
PCA analysis extracted 4 significant factors in the both
groups, whereas extracted factors containing »octacosanol
status« variable explained 14.7% and 11.5% of the variance
in responders’ and non-responders’ subgroups, respectively.
Conclusions: Octacosanol supplementation leads to an
improvement of lipid profile and markers of redox status in
responders’ group. New studies are needed to validate our
results in order to find the best approach for personalized
supplementation as a useful adjunct to standard statin
therapy.
AB  - Uvod: Neujednačeni hipolipemijski efekti primene statina kao i intolerancija na statine dovode do porasta inte resovanja u vezi sa zajedničkom primenom statina i dijetetskih suplemenata. Ova studija je imala za cilj da proceni efekte suplementacije oktakozanolom na markere redoks statusa kod kardiovaskularnih pacijenata na hroničnoj terapiji atorvastatinom. Metode: Sprovedena je dvostruko slepa, randomizovana, placebo kontrolisana studija. U serumu 81 pacijenta određivani su parametri redoks statusa [produkti uznapredovale oksidacije proteina (AOPP), prooksidativno-antioksidativni balans (PAB), totalni oksidativni status (TOS), totalni antioksidativni status (TAS), aktivnost superoksid dismutaze (SOD), sulfihidrilne grupe (SH-grupe) i aktivnost paraoksonaze 1 (PON1)]. U odnosu na povoljne promene lipidnog profila, pacijenti su klasifikovani u dve grupe: responderi (n = 35) i neresponderi (n = 46), i praćeni su 13 nedelja. Rezultati: Značajno smanjenje vrednosti oksi-skora primećeno je kod respondera na kraju studije u poređenju sa vrednostima na početku studije (21,0 (1 3,4 -25,5) vs. 15,1 (12,4 -18,0); P < 0,01). Principal component analiza (PCA) je primenjena da bi se procenio efekat suplementacije oktakozanolom kao i odnos između ispitivanih parametara kao prediktora odgovara u obe grupe. PCA analiza je izdvojila po 4 značajna faktora u obe grupe, pri čemu faktori koji sadrže varijablu "status oktakozanola" objašnjavaju 14,7% i 11,5% ukupne varijacije kod respondera i nerespondera, redom. Zaključak: Suplementacija oktakozanolom dovodi do poboljšanja lipidnog profila i markera redoks statusa u grupi respondera. Buduće studije su potrebne za potvrdu dobijenih rezultata a u cilju pronalaženja optimalnog pristupa za personalizovanu suplementaciju uz standardnu terapiju statinima.
PB  - Beograd : Društvo medicinskih biohemičara Srbije
T2  - Journal of Medical Biochemistry
T1  - Association of octacosanol supplementation with redox status in patients on chronic statin therapy
T1  - Povezanost suplementacije oktakozanolom i parametara redoks statusa kod pacijenata na hroničnoj terapiji atorvastatinom
VL  - 42
IS  - 1
SP  - 47
EP  - 57
DO  - 10.5937/jomb0-38224
ER  - 

@article{
author = "Zrnić-Ćirić, Milica and Kotur-Stevuljević, Jelena and Stanković, Ivan and Đorđević, Brižita and Baralić, Ivana and Ostojić, Miodrag",
year = "2023",
abstract = "Background: The uneven lipid-lowering statin effects and
statin intolerance raise interest regarding the involvement
of coadministration of statins and dietary supplements.
This study aimed to evaluate the effects of octacosanol
supplementation on markers of redox status in cardiovascular patients on chronic atorvastatin therapy.
Methods: A double-blind, randomized, placebo-controlled,
single-centre study was conducted. Redox status home-
ostasis parameters  i.e., advanced oxidation protein products (AOPP), pro-oxidant-antioxidant balance (PAB), total
oxidant status (TOS), total antioxidant status (TAS), superoxide dismutase activity (SOD), total protein sulfhydryl (SH-
groups), and paraoxonase 1 (PON1) activity  were
assessed in 81 patients. According to favorable changes in
lipid profile, patients were classified into two groups:
responders (n = 35) and non-responders (n = 46), and
followed for 13 weeks. A principal component analysis
(PCA) was applied to explore the effect of octacosanol supplementation and the relationship between investigated
parameters as predictors of responders’ and non-responders’ status.
Results: Significant decrease in Oxy-score value was found
at the endpoint compared to baseline in responders’ group (21.0 (13.4–25.5) versus 15.1 (12.4–18.0); P < 0.01).
PCA analysis extracted 4 significant factors in the both
groups, whereas extracted factors containing »octacosanol
status« variable explained 14.7% and 11.5% of the variance
in responders’ and non-responders’ subgroups, respectively.
Conclusions: Octacosanol supplementation leads to an
improvement of lipid profile and markers of redox status in
responders’ group. New studies are needed to validate our
results in order to find the best approach for personalized
supplementation as a useful adjunct to standard statin
therapy., Uvod: Neujednačeni hipolipemijski efekti primene statina kao i intolerancija na statine dovode do porasta inte resovanja u vezi sa zajedničkom primenom statina i dijetetskih suplemenata. Ova studija je imala za cilj da proceni efekte suplementacije oktakozanolom na markere redoks statusa kod kardiovaskularnih pacijenata na hroničnoj terapiji atorvastatinom. Metode: Sprovedena je dvostruko slepa, randomizovana, placebo kontrolisana studija. U serumu 81 pacijenta određivani su parametri redoks statusa [produkti uznapredovale oksidacije proteina (AOPP), prooksidativno-antioksidativni balans (PAB), totalni oksidativni status (TOS), totalni antioksidativni status (TAS), aktivnost superoksid dismutaze (SOD), sulfihidrilne grupe (SH-grupe) i aktivnost paraoksonaze 1 (PON1)]. U odnosu na povoljne promene lipidnog profila, pacijenti su klasifikovani u dve grupe: responderi (n = 35) i neresponderi (n = 46), i praćeni su 13 nedelja. Rezultati: Značajno smanjenje vrednosti oksi-skora primećeno je kod respondera na kraju studije u poređenju sa vrednostima na početku studije (21,0 (1 3,4 -25,5) vs. 15,1 (12,4 -18,0); P < 0,01). Principal component analiza (PCA) je primenjena da bi se procenio efekat suplementacije oktakozanolom kao i odnos između ispitivanih parametara kao prediktora odgovara u obe grupe. PCA analiza je izdvojila po 4 značajna faktora u obe grupe, pri čemu faktori koji sadrže varijablu "status oktakozanola" objašnjavaju 14,7% i 11,5% ukupne varijacije kod respondera i nerespondera, redom. Zaključak: Suplementacija oktakozanolom dovodi do poboljšanja lipidnog profila i markera redoks statusa u grupi respondera. Buduće studije su potrebne za potvrdu dobijenih rezultata a u cilju pronalaženja optimalnog pristupa za personalizovanu suplementaciju uz standardnu terapiju statinima.",
publisher = "Beograd : Društvo medicinskih biohemičara Srbije",
journal = "Journal of Medical Biochemistry",
title = "Association of octacosanol supplementation with redox status in patients on chronic statin therapy, Povezanost suplementacije oktakozanolom i parametara redoks statusa kod pacijenata na hroničnoj terapiji atorvastatinom",
volume = "42",
number = "1",
pages = "47-57",
doi = "10.5937/jomb0-38224"
}

Zrnić-Ćirić, M., Kotur-Stevuljević, J., Stanković, I., Đorđević, B., Baralić, I.,& Ostojić, M.. (2023). Association of octacosanol supplementation with redox status in patients on chronic statin therapy. in Journal of Medical Biochemistry
Beograd : Društvo medicinskih biohemičara Srbije., 42(1), 47-57.
https://doi.org/10.5937/jomb0-38224

Zrnić-Ćirić M, Kotur-Stevuljević J, Stanković I, Đorđević B, Baralić I, Ostojić M. Association of octacosanol supplementation with redox status in patients on chronic statin therapy. in Journal of Medical Biochemistry. 2023;42(1):47-57.
doi:10.5937/jomb0-38224 .

Zrnić-Ćirić, Milica, Kotur-Stevuljević, Jelena, Stanković, Ivan, Đorđević, Brižita, Baralić, Ivana, Ostojić, Miodrag, "Association of octacosanol supplementation with redox status in patients on chronic statin therapy" in Journal of Medical Biochemistry, 42, no. 1 (2023):47-57,
https://doi.org/10.5937/jomb0-38224 . .

TY  - JOUR
AU  - Zrnić-Ćirić, Milica
AU  - Ostojić, Miodrag
AU  - Baralić, Ivana
AU  - Kotur-Stevuljević, Jelena
AU  - Đorđević, Brižita
AU  - Marković, Stana
AU  - Živković, Stefan
AU  - Stanković, Ivan
PY  - 2021
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/3818
AB  - Dietary supplementation with sugar cane derivates may modulate low-density lipoproteincholesterol (LDL-C) and proprotein convertase subtilisin/kexin type 9 (PCSK9) levels. The purposeof this study was to determine if dietary supplement (DS), containing Octacosanol (20 mg) andvitamin K2 (45μg), could restore the disrupted physiologic relation between LDL-C and serumPCSK9. Double-blind, randomized, placebo-controlled, single-center study including 87 patients onchronic atorvastatin therapy was conducted. Eighty-seven patients were randomized to receive DS(n= 42) or placebo (n= 45), and followed for 13 weeks. Serum PCSK9 levels, lipid parameters andtheir relationship were the main efficacy endpoints. The absolute levels of PCSK9 and LDL-C werenot significantly different from baseline to 13 weeks. However, physiologic correlation between %change of PCSK9 and % change of LDL-C levels was normalized only in the group of patients treatedwith DS (r= 0.409,p= 0.012).  This study shows that DS can restore statin disrupted physiologicpositive correlation between PCSK9 and LDL-C. Elevated PCSK9 level is an independent risk factorso controlling its rise by statins may be important in prevention of cardiovascular events.
PB  - MDPI
T2  - Nutrients
T1  - Supplementation with Octacosanol Affects the Level of PCSK9 and Restore Its Physiologic Relation with LDL-C in Patients on Chronic Statin Therapy
VL  - 13
IS  - 3
DO  - 10.3390/nu13030903
ER  - 

@article{
author = "Zrnić-Ćirić, Milica and Ostojić, Miodrag and Baralić, Ivana and Kotur-Stevuljević, Jelena and Đorđević, Brižita and Marković, Stana and Živković, Stefan and Stanković, Ivan",
year = "2021",
abstract = "Dietary supplementation with sugar cane derivates may modulate low-density lipoproteincholesterol (LDL-C) and proprotein convertase subtilisin/kexin type 9 (PCSK9) levels. The purposeof this study was to determine if dietary supplement (DS), containing Octacosanol (20 mg) andvitamin K2 (45μg), could restore the disrupted physiologic relation between LDL-C and serumPCSK9. Double-blind, randomized, placebo-controlled, single-center study including 87 patients onchronic atorvastatin therapy was conducted. Eighty-seven patients were randomized to receive DS(n= 42) or placebo (n= 45), and followed for 13 weeks. Serum PCSK9 levels, lipid parameters andtheir relationship were the main efficacy endpoints. The absolute levels of PCSK9 and LDL-C werenot significantly different from baseline to 13 weeks. However, physiologic correlation between %change of PCSK9 and % change of LDL-C levels was normalized only in the group of patients treatedwith DS (r= 0.409,p= 0.012).  This study shows that DS can restore statin disrupted physiologicpositive correlation between PCSK9 and LDL-C. Elevated PCSK9 level is an independent risk factorso controlling its rise by statins may be important in prevention of cardiovascular events.",
publisher = "MDPI",
journal = "Nutrients",
title = "Supplementation with Octacosanol Affects the Level of PCSK9 and Restore Its Physiologic Relation with LDL-C in Patients on Chronic Statin Therapy",
volume = "13",
number = "3",
doi = "10.3390/nu13030903"
}

Zrnić-Ćirić, M., Ostojić, M., Baralić, I., Kotur-Stevuljević, J., Đorđević, B., Marković, S., Živković, S.,& Stanković, I.. (2021). Supplementation with Octacosanol Affects the Level of PCSK9 and Restore Its Physiologic Relation with LDL-C in Patients on Chronic Statin Therapy. in Nutrients
MDPI., 13(3).
https://doi.org/10.3390/nu13030903

Zrnić-Ćirić M, Ostojić M, Baralić I, Kotur-Stevuljević J, Đorđević B, Marković S, Živković S, Stanković I. Supplementation with Octacosanol Affects the Level of PCSK9 and Restore Its Physiologic Relation with LDL-C in Patients on Chronic Statin Therapy. in Nutrients. 2021;13(3).
doi:10.3390/nu13030903 .

Zrnić-Ćirić, Milica, Ostojić, Miodrag, Baralić, Ivana, Kotur-Stevuljević, Jelena, Đorđević, Brižita, Marković, Stana, Živković, Stefan, Stanković, Ivan, "Supplementation with Octacosanol Affects the Level of PCSK9 and Restore Its Physiologic Relation with LDL-C in Patients on Chronic Statin Therapy" in Nutrients, 13, no. 3 (2021),
https://doi.org/10.3390/nu13030903 . .

TY  - JOUR
AU  - Popović, Dejana
AU  - Guazzi, Marco
AU  - Jakovljević, Đorđe G.
AU  - Lasica, Ratko
AU  - Banović, Marko
AU  - Ostojić, Miodrag
AU  - Arena, Ross
PY  - 2019
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/3316
AB  - Background: This study examined the accuracy of cardiopulmonary exercise testing (CPET) on a treadmill (TM) and recumbent ergometry (RE) in the predicting coronary artery disease (CAD) severity and prognosis. Methods: Forty Caucasian subjects, mean age 63.5 +/- 7.6, with significant coronary artery lesions (>= 50%) were included. Within two months of coronary angiography, TM and RE CPET were performed on two visits 2-4 days apart and subsequently followed up to 32 +/- 10 months. Results: Mean left ventricular ejection fraction was 56.7 +/- 9.6%. TM CPET exhibited a higher occurrence of ST segment depression >= 1 mm (71.05% vs 28.95%, p = 0.04). Subjects with 1-2 stenotic coronary arteries (SCA) demonstrated a better CPET response compared to those with 3-SCA. ROC analysis revealed a high predictive value for the ventilation/carbon dioxide production (VE/VCO2) slope obtained on TM (area 0.84, p = 0.003, Sn 88.9%, Sp 72%) in distinguishing between 1 and 2-SCA and 3-SCA. Among all CPET parameters, work efficiency (Delta VO2/Delta WR) during RE predicted cumulative cardiac events (p  lt  0.01). Conclusions: CPET parameters hold predictive value for CAD severity and prognosis. CPET on a TM appears to be more reliable in the quantification of CAD compared to RE.
PB  - Elsevier Ireland Ltd, Clare
T2  - International Journal of Cardiology
T1  - Quantification of coronary artery disease using different modalities of cardiopulmonary exercise testing
VL  - 285
SP  - 11
EP  - 13
DO  - 10.1016/j.ijcard.2019.03.012
ER  - 

@article{
author = "Popović, Dejana and Guazzi, Marco and Jakovljević, Đorđe G. and Lasica, Ratko and Banović, Marko and Ostojić, Miodrag and Arena, Ross",
year = "2019",
abstract = "Background: This study examined the accuracy of cardiopulmonary exercise testing (CPET) on a treadmill (TM) and recumbent ergometry (RE) in the predicting coronary artery disease (CAD) severity and prognosis. Methods: Forty Caucasian subjects, mean age 63.5 +/- 7.6, with significant coronary artery lesions (>= 50%) were included. Within two months of coronary angiography, TM and RE CPET were performed on two visits 2-4 days apart and subsequently followed up to 32 +/- 10 months. Results: Mean left ventricular ejection fraction was 56.7 +/- 9.6%. TM CPET exhibited a higher occurrence of ST segment depression >= 1 mm (71.05% vs 28.95%, p = 0.04). Subjects with 1-2 stenotic coronary arteries (SCA) demonstrated a better CPET response compared to those with 3-SCA. ROC analysis revealed a high predictive value for the ventilation/carbon dioxide production (VE/VCO2) slope obtained on TM (area 0.84, p = 0.003, Sn 88.9%, Sp 72%) in distinguishing between 1 and 2-SCA and 3-SCA. Among all CPET parameters, work efficiency (Delta VO2/Delta WR) during RE predicted cumulative cardiac events (p  lt  0.01). Conclusions: CPET parameters hold predictive value for CAD severity and prognosis. CPET on a TM appears to be more reliable in the quantification of CAD compared to RE.",
publisher = "Elsevier Ireland Ltd, Clare",
journal = "International Journal of Cardiology",
title = "Quantification of coronary artery disease using different modalities of cardiopulmonary exercise testing",
volume = "285",
pages = "11-13",
doi = "10.1016/j.ijcard.2019.03.012"
}

Popović, D., Guazzi, M., Jakovljević, Đ. G., Lasica, R., Banović, M., Ostojić, M.,& Arena, R.. (2019). Quantification of coronary artery disease using different modalities of cardiopulmonary exercise testing. in International Journal of Cardiology
Elsevier Ireland Ltd, Clare., 285, 11-13.
https://doi.org/10.1016/j.ijcard.2019.03.012

Popović D, Guazzi M, Jakovljević ĐG, Lasica R, Banović M, Ostojić M, Arena R. Quantification of coronary artery disease using different modalities of cardiopulmonary exercise testing. in International Journal of Cardiology. 2019;285:11-13.
doi:10.1016/j.ijcard.2019.03.012 .

Popović, Dejana, Guazzi, Marco, Jakovljević, Đorđe G., Lasica, Ratko, Banović, Marko, Ostojić, Miodrag, Arena, Ross, "Quantification of coronary artery disease using different modalities of cardiopulmonary exercise testing" in International Journal of Cardiology, 285 (2019):11-13,
https://doi.org/10.1016/j.ijcard.2019.03.012 . .

TY  - JOUR
AU  - Dobrić, Milan
AU  - Giga, Vojislav
AU  - Beleslin, Branko
AU  - Ignjatović, Svetlana
AU  - Paunović, Ivana
AU  - Stepanović, Jelena M.
AU  - Đorđević-Dikić, Ana
AU  - Kostić, Jelena
AU  - Nedeljković, Ivana
AU  - Nedeljković, Milan
AU  - Tesić, Milorad
AU  - Dajak, Marijana
AU  - Ostojić, Miodrag
PY  - 2013
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/1868
AB  - Background: Glycogen phosphorylase BB (GPBB) is released from cardiac cells during myocyte damage. Previous studies have shown contradictory results regarding the relation of enzyme release and reversible myocardial ischemia. The aim of this study was to determine the plasma kinetics of GPBB as a response to the exercise stress echocardiographic test (ESET), and to define the relationship between myocardial ischemia and enzyme plasma concentrations. Methods: We studied 46 consecutive patients undergoing ESET, with recent coronary angiography. In all patients, a submaximal stress echo test according to Bruce protocol was performed. Concentration of GPBB was measured in peripheral blood that was sampled 5 min before and 10, 30 and 60 min after ESET. Results: There was significant increase of GPBB concentration after the test (p=0.021). Significant increase was detected 30 min (34.9% increase, p=0.021) and 60 min (34.5% increase, p=0.016) after ESET. There was no significant effect of myocardial ischemia on GPBB concentrations (p=0.126), and no significant interaction between sampling intervals and myocardial ischemia, suggesting a similar release profile of GPBB in ischemic and non-ischemic conditions (p=0.558). Patients in whom ESET was terminated later (stages 4 or 5 of standard Bruce protocol; n=13) had higher GPBB concentrations than patients who terminated ESET earlier (stages 1, 2 or 3; n=33) (p=0.049). Baseline GPBB concentration was not correlated to any of the patients' demographic, clinical and hemodynamic characteristics. Conclusions: GPBB plasma concentration increases after ESET, and it is not related to inducible myocardial ischemia. However, it seems that GPBB release during ESET might be related to exercise load/duration.
PB  - Walter de Gruyter Gmbh, Berlin
T2  - Clinical Chemistry and Laboratory Medicine
T1  - Glycogen phosphorylase isoenzyme BB plasma kinetics is not related to myocardial ischemia induced by exercise stress echo test
VL  - 51
IS  - 10
SP  - 2029
EP  - 2035
DO  - 10.1515/cclm-2013-0109
ER  - 

@article{
author = "Dobrić, Milan and Giga, Vojislav and Beleslin, Branko and Ignjatović, Svetlana and Paunović, Ivana and Stepanović, Jelena M. and Đorđević-Dikić, Ana and Kostić, Jelena and Nedeljković, Ivana and Nedeljković, Milan and Tesić, Milorad and Dajak, Marijana and Ostojić, Miodrag",
year = "2013",
abstract = "Background: Glycogen phosphorylase BB (GPBB) is released from cardiac cells during myocyte damage. Previous studies have shown contradictory results regarding the relation of enzyme release and reversible myocardial ischemia. The aim of this study was to determine the plasma kinetics of GPBB as a response to the exercise stress echocardiographic test (ESET), and to define the relationship between myocardial ischemia and enzyme plasma concentrations. Methods: We studied 46 consecutive patients undergoing ESET, with recent coronary angiography. In all patients, a submaximal stress echo test according to Bruce protocol was performed. Concentration of GPBB was measured in peripheral blood that was sampled 5 min before and 10, 30 and 60 min after ESET. Results: There was significant increase of GPBB concentration after the test (p=0.021). Significant increase was detected 30 min (34.9% increase, p=0.021) and 60 min (34.5% increase, p=0.016) after ESET. There was no significant effect of myocardial ischemia on GPBB concentrations (p=0.126), and no significant interaction between sampling intervals and myocardial ischemia, suggesting a similar release profile of GPBB in ischemic and non-ischemic conditions (p=0.558). Patients in whom ESET was terminated later (stages 4 or 5 of standard Bruce protocol; n=13) had higher GPBB concentrations than patients who terminated ESET earlier (stages 1, 2 or 3; n=33) (p=0.049). Baseline GPBB concentration was not correlated to any of the patients' demographic, clinical and hemodynamic characteristics. Conclusions: GPBB plasma concentration increases after ESET, and it is not related to inducible myocardial ischemia. However, it seems that GPBB release during ESET might be related to exercise load/duration.",
publisher = "Walter de Gruyter Gmbh, Berlin",
journal = "Clinical Chemistry and Laboratory Medicine",
title = "Glycogen phosphorylase isoenzyme BB plasma kinetics is not related to myocardial ischemia induced by exercise stress echo test",
volume = "51",
number = "10",
pages = "2029-2035",
doi = "10.1515/cclm-2013-0109"
}

Dobrić, M., Giga, V., Beleslin, B., Ignjatović, S., Paunović, I., Stepanović, J. M., Đorđević-Dikić, A., Kostić, J., Nedeljković, I., Nedeljković, M., Tesić, M., Dajak, M.,& Ostojić, M.. (2013). Glycogen phosphorylase isoenzyme BB plasma kinetics is not related to myocardial ischemia induced by exercise stress echo test. in Clinical Chemistry and Laboratory Medicine
Walter de Gruyter Gmbh, Berlin., 51(10), 2029-2035.
https://doi.org/10.1515/cclm-2013-0109

Dobrić M, Giga V, Beleslin B, Ignjatović S, Paunović I, Stepanović JM, Đorđević-Dikić A, Kostić J, Nedeljković I, Nedeljković M, Tesić M, Dajak M, Ostojić M. Glycogen phosphorylase isoenzyme BB plasma kinetics is not related to myocardial ischemia induced by exercise stress echo test. in Clinical Chemistry and Laboratory Medicine. 2013;51(10):2029-2035.
doi:10.1515/cclm-2013-0109 .

Dobrić, Milan, Giga, Vojislav, Beleslin, Branko, Ignjatović, Svetlana, Paunović, Ivana, Stepanović, Jelena M., Đorđević-Dikić, Ana, Kostić, Jelena, Nedeljković, Ivana, Nedeljković, Milan, Tesić, Milorad, Dajak, Marijana, Ostojić, Miodrag, "Glycogen phosphorylase isoenzyme BB plasma kinetics is not related to myocardial ischemia induced by exercise stress echo test" in Clinical Chemistry and Laboratory Medicine, 51, no. 10 (2013):2029-2035,
https://doi.org/10.1515/cclm-2013-0109 . .

TY  - JOUR
AU  - Popović, Dejana
AU  - Popović, Bojana
AU  - Plećaš-Solarović, Bosiljka
AU  - Pešić, Vesna
AU  - Marković, Vidan
AU  - Stojiljković, Stanimir
AU  - Vukcević, Vladan
AU  - Petrović, Ivana
AU  - Banović, Marko
AU  - Petrović, Milan
AU  - Vujisić-Tesić, Bosiljka
AU  - Ostojić, Miodrag
AU  - Ristić, Arsen
AU  - Damjanović, Svetozar S.
PY  - 2013
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/1857
AB  - Brain natriuretic peptide (NT-pro-BNP) was implicated in the regulation of hypothalamic-pituitary-adrenocortical (HPA) responses to psychological stressors. However, HPA axis activation in different physical stress models and its interface with NT-pro-BNP in the prediction of cardiopulmonary performance is unclear. Cardiopulmonary test on a treadmill was used to assess cardiopulmonary parameters in 16 elite male wrestlers (W), 21 water polo player (WP) and 20 sedentary age-matched subjects
PB  - Elsevier Science Inc, New York
T2  - Peptides
T1  - The interface of hypothalamic-pituitary-adrenocortical axis and circulating brain natriuretic peptide in prediction of cardiopulmonary performance during physical stress
VL  - 47
SP  - 85
EP  - 93
DO  - 10.1016/j.peptides.2013.07.009
ER  - 

@article{
author = "Popović, Dejana and Popović, Bojana and Plećaš-Solarović, Bosiljka and Pešić, Vesna and Marković, Vidan and Stojiljković, Stanimir and Vukcević, Vladan and Petrović, Ivana and Banović, Marko and Petrović, Milan and Vujisić-Tesić, Bosiljka and Ostojić, Miodrag and Ristić, Arsen and Damjanović, Svetozar S.",
year = "2013",
abstract = "Brain natriuretic peptide (NT-pro-BNP) was implicated in the regulation of hypothalamic-pituitary-adrenocortical (HPA) responses to psychological stressors. However, HPA axis activation in different physical stress models and its interface with NT-pro-BNP in the prediction of cardiopulmonary performance is unclear. Cardiopulmonary test on a treadmill was used to assess cardiopulmonary parameters in 16 elite male wrestlers (W), 21 water polo player (WP) and 20 sedentary age-matched subjects",
publisher = "Elsevier Science Inc, New York",
journal = "Peptides",
title = "The interface of hypothalamic-pituitary-adrenocortical axis and circulating brain natriuretic peptide in prediction of cardiopulmonary performance during physical stress",
volume = "47",
pages = "85-93",
doi = "10.1016/j.peptides.2013.07.009"
}

Popović, D., Popović, B., Plećaš-Solarović, B., Pešić, V., Marković, V., Stojiljković, S., Vukcević, V., Petrović, I., Banović, M., Petrović, M., Vujisić-Tesić, B., Ostojić, M., Ristić, A.,& Damjanović, S. S.. (2013). The interface of hypothalamic-pituitary-adrenocortical axis and circulating brain natriuretic peptide in prediction of cardiopulmonary performance during physical stress. in Peptides
Elsevier Science Inc, New York., 47, 85-93.
https://doi.org/10.1016/j.peptides.2013.07.009

Popović D, Popović B, Plećaš-Solarović B, Pešić V, Marković V, Stojiljković S, Vukcević V, Petrović I, Banović M, Petrović M, Vujisić-Tesić B, Ostojić M, Ristić A, Damjanović SS. The interface of hypothalamic-pituitary-adrenocortical axis and circulating brain natriuretic peptide in prediction of cardiopulmonary performance during physical stress. in Peptides. 2013;47:85-93.
doi:10.1016/j.peptides.2013.07.009 .

Popović, Dejana, Popović, Bojana, Plećaš-Solarović, Bosiljka, Pešić, Vesna, Marković, Vidan, Stojiljković, Stanimir, Vukcević, Vladan, Petrović, Ivana, Banović, Marko, Petrović, Milan, Vujisić-Tesić, Bosiljka, Ostojić, Miodrag, Ristić, Arsen, Damjanović, Svetozar S., "The interface of hypothalamic-pituitary-adrenocortical axis and circulating brain natriuretic peptide in prediction of cardiopulmonary performance during physical stress" in Peptides, 47 (2013):85-93,
https://doi.org/10.1016/j.peptides.2013.07.009 . .

TY  - JOUR
AU  - Stanković, Sanja
AU  - Ašanin, Milika
AU  - Trifunović, Danijela
AU  - Majkić-Singh, Nada
AU  - Ignjatović, Svetlana
AU  - Mrdović, Igor
AU  - Matić, Dragan
AU  - Savić, Lidija
AU  - Marinković, Jelena
AU  - Ostojić, Miodrag
AU  - Vasiljević, Zorana
PY  - 2012
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/1752
AB  - Objectives: To analyze the prognostic value of myeloperoxidase (MPO) in relation to in-hospital mortality and to identify the optimum time point for sampling in patients with the first anterior ST-segment elevation myocardial infarction (STEMI) treated by primary percutaneous coronary intervention (pPCI). Design and methods: A total of 100 consecutive patients with the first anterior STEMI undergoing pPCI were included. Blood samples were collected at baseline, 4, 8, 12, 18, 24,48 and 168 hours (h) after pPCI. Results: MPO concentrations have showed a biphasic pattern over time; the highest MPO levels were at 4 h and 2411 after pPCI. In-hospital mortality was 6%. MPO at 24 h significantly correlated with troponin I as well as heart failure. After multivariate adjustment, MPO at 24 h was an independent predictor of the in-hospital mortality (OR 3.34, 95% CI 1.13-9.86, P = 0.029). Conclusions: In patients with the first anterior STEMI treated by pPCI. MPO at 24 h after procedure was an independent predictor of the in-hospital mortality.
PB  - Pergamon-Elsevier Science Ltd, Oxford
T2  - Clinical Biochemistry
T1  - Time-dependent changes of myeloperoxidase in relation to in-hospital mortality in patients with the first anterior ST-segment elevation myocardial infarction treated by primary percutaneous coronary intervention
VL  - 45
IS  - 7-8
SP  - 547
EP  - 551
DO  - 10.1016/j.clinbiochem.2012.02.015
ER  - 

@article{
author = "Stanković, Sanja and Ašanin, Milika and Trifunović, Danijela and Majkić-Singh, Nada and Ignjatović, Svetlana and Mrdović, Igor and Matić, Dragan and Savić, Lidija and Marinković, Jelena and Ostojić, Miodrag and Vasiljević, Zorana",
year = "2012",
abstract = "Objectives: To analyze the prognostic value of myeloperoxidase (MPO) in relation to in-hospital mortality and to identify the optimum time point for sampling in patients with the first anterior ST-segment elevation myocardial infarction (STEMI) treated by primary percutaneous coronary intervention (pPCI). Design and methods: A total of 100 consecutive patients with the first anterior STEMI undergoing pPCI were included. Blood samples were collected at baseline, 4, 8, 12, 18, 24,48 and 168 hours (h) after pPCI. Results: MPO concentrations have showed a biphasic pattern over time; the highest MPO levels were at 4 h and 2411 after pPCI. In-hospital mortality was 6%. MPO at 24 h significantly correlated with troponin I as well as heart failure. After multivariate adjustment, MPO at 24 h was an independent predictor of the in-hospital mortality (OR 3.34, 95% CI 1.13-9.86, P = 0.029). Conclusions: In patients with the first anterior STEMI treated by pPCI. MPO at 24 h after procedure was an independent predictor of the in-hospital mortality.",
publisher = "Pergamon-Elsevier Science Ltd, Oxford",
journal = "Clinical Biochemistry",
title = "Time-dependent changes of myeloperoxidase in relation to in-hospital mortality in patients with the first anterior ST-segment elevation myocardial infarction treated by primary percutaneous coronary intervention",
volume = "45",
number = "7-8",
pages = "547-551",
doi = "10.1016/j.clinbiochem.2012.02.015"
}

Stanković, S., Ašanin, M., Trifunović, D., Majkić-Singh, N., Ignjatović, S., Mrdović, I., Matić, D., Savić, L., Marinković, J., Ostojić, M.,& Vasiljević, Z.. (2012). Time-dependent changes of myeloperoxidase in relation to in-hospital mortality in patients with the first anterior ST-segment elevation myocardial infarction treated by primary percutaneous coronary intervention. in Clinical Biochemistry
Pergamon-Elsevier Science Ltd, Oxford., 45(7-8), 547-551.
https://doi.org/10.1016/j.clinbiochem.2012.02.015

Stanković S, Ašanin M, Trifunović D, Majkić-Singh N, Ignjatović S, Mrdović I, Matić D, Savić L, Marinković J, Ostojić M, Vasiljević Z. Time-dependent changes of myeloperoxidase in relation to in-hospital mortality in patients with the first anterior ST-segment elevation myocardial infarction treated by primary percutaneous coronary intervention. in Clinical Biochemistry. 2012;45(7-8):547-551.
doi:10.1016/j.clinbiochem.2012.02.015 .

Stanković, Sanja, Ašanin, Milika, Trifunović, Danijela, Majkić-Singh, Nada, Ignjatović, Svetlana, Mrdović, Igor, Matić, Dragan, Savić, Lidija, Marinković, Jelena, Ostojić, Miodrag, Vasiljević, Zorana, "Time-dependent changes of myeloperoxidase in relation to in-hospital mortality in patients with the first anterior ST-segment elevation myocardial infarction treated by primary percutaneous coronary intervention" in Clinical Biochemistry, 45, no. 7-8 (2012):547-551,
https://doi.org/10.1016/j.clinbiochem.2012.02.015 . .

TY  - JOUR
AU  - Stanković, Sanja
AU  - Ašanin, Milika
AU  - Majkić-Singh, Nada
AU  - Ignjatović, Svetlana
AU  - Mihailović, Mirjana
AU  - Nikolajević, Ivica
AU  - Mrdović, Igor
AU  - Matić, Dragan
AU  - Savić, Lidija
AU  - Marinković, Jelena
AU  - Ostojić, Miodrag
AU  - Vasiljević, Zorana
PY  - 2012
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/1701
AB  - Background: The predictive value of myeloperoxidase (MPO) in ST-segment elevation myocardial infarction (STEM I) treated by primary percutaneous coronary intervention (PCI) has not been established. The aim of the present study was to investigate MPO as a predictor of in-hospital mortality in STEMI patients treated by primary PCI. Methods: Study population consisted of 189 STEMI patients having undergone primary PCI. Plasma MPO level was measured 24 hours after symptom onset using chemiluminescent microparticle immunoassay (Abbott Diagnostics, Germany). The Receiver Operating Characteristic analysis was performed to identify the most useful MPO cut-off level for the prediction of in-hospital mortality. The patients were divided into two groups according to the cut-off MPO level: high MPO group (>= 840 pmol/L, n = 65) and low M PO group ( lt 840 pmol/L, n = 124). Results: The high M PO group had significantly more frequent anterior wall infarctions (p lt 0.001) and Killip class >1 on admission (p=0.013) as well as lower left ventricular ejection fraction (LVEF) (p=0.011) and higher B-type natriuretic peptide (BNP) (p=0.029) than the low MPO group. The incidence of in-hospital mortality was 5.8% and was significantly higher in the high M PO group (13.8%) than in the low MPO group (1.6%) (p=0.001). Multiple logistic regression analysis identified the plasma MPO level as an independent predictor of in-hospital mortality (OR 3.88, 95%CI 1.13 - 13.34, p=0.031). Conclusions: Plasma M PO level independently predicts in-hospital mortality in STEMI patients treated by primary PCI. (Clin. Lab. 2012;58:125-131)
PB  - Clin Lab Publ, Heidelberg
T2  - Clinical Laboratory
T1  - The Usefulness of Myeloperoxidase in Prediction of In-Hospital Mortality in Patients with ST-Segment Elevation Myocardial Infarction Treated by Primary Percutaneous Coronary Intervention
VL  - 58
IS  - 1-2
SP  - 125
EP  - 131
UR  - https://hdl.handle.net/21.15107/rcub_farfar_1701
ER  - 

@article{
author = "Stanković, Sanja and Ašanin, Milika and Majkić-Singh, Nada and Ignjatović, Svetlana and Mihailović, Mirjana and Nikolajević, Ivica and Mrdović, Igor and Matić, Dragan and Savić, Lidija and Marinković, Jelena and Ostojić, Miodrag and Vasiljević, Zorana",
year = "2012",
abstract = "Background: The predictive value of myeloperoxidase (MPO) in ST-segment elevation myocardial infarction (STEM I) treated by primary percutaneous coronary intervention (PCI) has not been established. The aim of the present study was to investigate MPO as a predictor of in-hospital mortality in STEMI patients treated by primary PCI. Methods: Study population consisted of 189 STEMI patients having undergone primary PCI. Plasma MPO level was measured 24 hours after symptom onset using chemiluminescent microparticle immunoassay (Abbott Diagnostics, Germany). The Receiver Operating Characteristic analysis was performed to identify the most useful MPO cut-off level for the prediction of in-hospital mortality. The patients were divided into two groups according to the cut-off MPO level: high MPO group (>= 840 pmol/L, n = 65) and low M PO group ( lt 840 pmol/L, n = 124). Results: The high M PO group had significantly more frequent anterior wall infarctions (p lt 0.001) and Killip class >1 on admission (p=0.013) as well as lower left ventricular ejection fraction (LVEF) (p=0.011) and higher B-type natriuretic peptide (BNP) (p=0.029) than the low MPO group. The incidence of in-hospital mortality was 5.8% and was significantly higher in the high M PO group (13.8%) than in the low MPO group (1.6%) (p=0.001). Multiple logistic regression analysis identified the plasma MPO level as an independent predictor of in-hospital mortality (OR 3.88, 95%CI 1.13 - 13.34, p=0.031). Conclusions: Plasma M PO level independently predicts in-hospital mortality in STEMI patients treated by primary PCI. (Clin. Lab. 2012;58:125-131)",
publisher = "Clin Lab Publ, Heidelberg",
journal = "Clinical Laboratory",
title = "The Usefulness of Myeloperoxidase in Prediction of In-Hospital Mortality in Patients with ST-Segment Elevation Myocardial Infarction Treated by Primary Percutaneous Coronary Intervention",
volume = "58",
number = "1-2",
pages = "125-131",
url = "https://hdl.handle.net/21.15107/rcub_farfar_1701"
}

Stanković, S., Ašanin, M., Majkić-Singh, N., Ignjatović, S., Mihailović, M., Nikolajević, I., Mrdović, I., Matić, D., Savić, L., Marinković, J., Ostojić, M.,& Vasiljević, Z.. (2012). The Usefulness of Myeloperoxidase in Prediction of In-Hospital Mortality in Patients with ST-Segment Elevation Myocardial Infarction Treated by Primary Percutaneous Coronary Intervention. in Clinical Laboratory
Clin Lab Publ, Heidelberg., 58(1-2), 125-131.
https://hdl.handle.net/21.15107/rcub_farfar_1701

Stanković S, Ašanin M, Majkić-Singh N, Ignjatović S, Mihailović M, Nikolajević I, Mrdović I, Matić D, Savić L, Marinković J, Ostojić M, Vasiljević Z. The Usefulness of Myeloperoxidase in Prediction of In-Hospital Mortality in Patients with ST-Segment Elevation Myocardial Infarction Treated by Primary Percutaneous Coronary Intervention. in Clinical Laboratory. 2012;58(1-2):125-131.
https://hdl.handle.net/21.15107/rcub_farfar_1701 .

Stanković, Sanja, Ašanin, Milika, Majkić-Singh, Nada, Ignjatović, Svetlana, Mihailović, Mirjana, Nikolajević, Ivica, Mrdović, Igor, Matić, Dragan, Savić, Lidija, Marinković, Jelena, Ostojić, Miodrag, Vasiljević, Zorana, "The Usefulness of Myeloperoxidase in Prediction of In-Hospital Mortality in Patients with ST-Segment Elevation Myocardial Infarction Treated by Primary Percutaneous Coronary Intervention" in Clinical Laboratory, 58, no. 1-2 (2012):125-131,
https://hdl.handle.net/21.15107/rcub_farfar_1701 .

TY  - JOUR
AU  - Stanković, Sanja
AU  - Ašanin, Milika
AU  - Trifunović, Danijela
AU  - Majkić-Singh, Nada
AU  - Miljković, Aleksandar
AU  - Ignjatović, Svetlana
AU  - Mrdović, Igor
AU  - Matić, Dragan
AU  - Savić, Lidija
AU  - Ostojić, Miodrag
AU  - Vasiljević, Zorana
PY  - 2012
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/1687
AB  - Background: Lipoprotein-associated phospholipase A(2) (Lp-PLA(2)) has been suggested as an inflammatory marker of cardiovascular risk. The predictive value of Lp-PLA(2) in ST-segment elevation myocardial infarction (STEMI) treated by primary percutaneous coronary intervention (PCI) has not been established. The aim of this study was to determine whether plasma Lp-PLA(2) is a predictor of a major adverse cardiac event (MACE) in patients with the first anterior STEMI treated by primary PCI. Methods: This study consisted of 100 consecutive patients with first anterior STEMI who underwent primary PCI within 6 hours of the symptom onset. Plasma Lp-PLA(2) level was measured on admission using a turbidimetric immunoassay (diaDexus, Inc., USA). The Receiver Operating Characteristic analysis was performed to identify the most useful Lp-PLA(2) cut-off level for the prediction of MACE. The patients were divided into two groups according to the cut-off Lp-PLA(2) level: high Lp-PLA(2) group (>= 463 ng/mL, n = 33) and low Lp-PLA(2) group ( lt  463 ng/mL, n = 67). MACE was defined as cardiac death, non-fatal reinfarction, and target vessel revascularization. Results: Patients in the high Lp-PLA(2) group had significantly higher total-, LDL-cholesterol, apolipoprotein B levels, and significantly lower estimated glomerular filtration rates compared with the low Lp-PLA(2) group. The incidence of 30-day mortality was 18.2% (6/33) in high Lp-PLA(2) group, while in the low Lp-PLA(2) group no patient died (p  lt  0.001). The 30-day MACE occurred in 24.2% of the high Lp-PLA(2) group and 3% of the low Lp-PLA(2) group (p = 0.001). Multiple logistic regression analysis identified the plasma Lp-PLA(2) level as an independent predictor of MACE (OR 1.011, 95%CI 1.001 - 1.013, p = 0.037). Conclusions: In patients with first anterior STEMI treated by primary PCI, the plasma Lp-PLA(2) level is an independent predictor of 30-day MACE. (Clin. Lab. 2012;58:1135-1144. DOI: 10.7754/Clin.Lab.2012.111102)
PB  - Clin Lab Publ, Heidelberg
T2  - Clinical Laboratory
T1  - Utility of Lipoprotein-Associated Phospholipase A(2) for Prediction of 30-day Major Adverse Coronary Event in Patients with the First Anterior ST-Segment Elevation Myocardial Infarction Treated by Primary Percutaneous Coronary Intervention
VL  - 58
IS  - 11-12
SP  - 1135
EP  - 1144
DO  - 10.7754/Clin.Lab.2012.111102
ER  - 

@article{
author = "Stanković, Sanja and Ašanin, Milika and Trifunović, Danijela and Majkić-Singh, Nada and Miljković, Aleksandar and Ignjatović, Svetlana and Mrdović, Igor and Matić, Dragan and Savić, Lidija and Ostojić, Miodrag and Vasiljević, Zorana",
year = "2012",
abstract = "Background: Lipoprotein-associated phospholipase A(2) (Lp-PLA(2)) has been suggested as an inflammatory marker of cardiovascular risk. The predictive value of Lp-PLA(2) in ST-segment elevation myocardial infarction (STEMI) treated by primary percutaneous coronary intervention (PCI) has not been established. The aim of this study was to determine whether plasma Lp-PLA(2) is a predictor of a major adverse cardiac event (MACE) in patients with the first anterior STEMI treated by primary PCI. Methods: This study consisted of 100 consecutive patients with first anterior STEMI who underwent primary PCI within 6 hours of the symptom onset. Plasma Lp-PLA(2) level was measured on admission using a turbidimetric immunoassay (diaDexus, Inc., USA). The Receiver Operating Characteristic analysis was performed to identify the most useful Lp-PLA(2) cut-off level for the prediction of MACE. The patients were divided into two groups according to the cut-off Lp-PLA(2) level: high Lp-PLA(2) group (>= 463 ng/mL, n = 33) and low Lp-PLA(2) group ( lt  463 ng/mL, n = 67). MACE was defined as cardiac death, non-fatal reinfarction, and target vessel revascularization. Results: Patients in the high Lp-PLA(2) group had significantly higher total-, LDL-cholesterol, apolipoprotein B levels, and significantly lower estimated glomerular filtration rates compared with the low Lp-PLA(2) group. The incidence of 30-day mortality was 18.2% (6/33) in high Lp-PLA(2) group, while in the low Lp-PLA(2) group no patient died (p  lt  0.001). The 30-day MACE occurred in 24.2% of the high Lp-PLA(2) group and 3% of the low Lp-PLA(2) group (p = 0.001). Multiple logistic regression analysis identified the plasma Lp-PLA(2) level as an independent predictor of MACE (OR 1.011, 95%CI 1.001 - 1.013, p = 0.037). Conclusions: In patients with first anterior STEMI treated by primary PCI, the plasma Lp-PLA(2) level is an independent predictor of 30-day MACE. (Clin. Lab. 2012;58:1135-1144. DOI: 10.7754/Clin.Lab.2012.111102)",
publisher = "Clin Lab Publ, Heidelberg",
journal = "Clinical Laboratory",
title = "Utility of Lipoprotein-Associated Phospholipase A(2) for Prediction of 30-day Major Adverse Coronary Event in Patients with the First Anterior ST-Segment Elevation Myocardial Infarction Treated by Primary Percutaneous Coronary Intervention",
volume = "58",
number = "11-12",
pages = "1135-1144",
doi = "10.7754/Clin.Lab.2012.111102"
}

Stanković, S., Ašanin, M., Trifunović, D., Majkić-Singh, N., Miljković, A., Ignjatović, S., Mrdović, I., Matić, D., Savić, L., Ostojić, M.,& Vasiljević, Z.. (2012). Utility of Lipoprotein-Associated Phospholipase A(2) for Prediction of 30-day Major Adverse Coronary Event in Patients with the First Anterior ST-Segment Elevation Myocardial Infarction Treated by Primary Percutaneous Coronary Intervention. in Clinical Laboratory
Clin Lab Publ, Heidelberg., 58(11-12), 1135-1144.
https://doi.org/10.7754/Clin.Lab.2012.111102

Stanković S, Ašanin M, Trifunović D, Majkić-Singh N, Miljković A, Ignjatović S, Mrdović I, Matić D, Savić L, Ostojić M, Vasiljević Z. Utility of Lipoprotein-Associated Phospholipase A(2) for Prediction of 30-day Major Adverse Coronary Event in Patients with the First Anterior ST-Segment Elevation Myocardial Infarction Treated by Primary Percutaneous Coronary Intervention. in Clinical Laboratory. 2012;58(11-12):1135-1144.
doi:10.7754/Clin.Lab.2012.111102 .

Stanković, Sanja, Ašanin, Milika, Trifunović, Danijela, Majkić-Singh, Nada, Miljković, Aleksandar, Ignjatović, Svetlana, Mrdović, Igor, Matić, Dragan, Savić, Lidija, Ostojić, Miodrag, Vasiljević, Zorana, "Utility of Lipoprotein-Associated Phospholipase A(2) for Prediction of 30-day Major Adverse Coronary Event in Patients with the First Anterior ST-Segment Elevation Myocardial Infarction Treated by Primary Percutaneous Coronary Intervention" in Clinical Laboratory, 58, no. 11-12 (2012):1135-1144,
https://doi.org/10.7754/Clin.Lab.2012.111102 . .

TY  - CONF
AU  - Lalić, K.
AU  - Zamaklar, M.
AU  - Lalić, N. M.
AU  - Ostojić, Miodrag
AU  - Kalimanovska, Vesna
AU  - Jotić, A.
AU  - Rajković, N.
AU  - Lukić, L.
AU  - Milicić, T.
AU  - Singh, Sandra
AU  - Stosić, L.
PY  - 2009
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/1257
PB  - Springer, New York
C3  - Diabetologia
T1  - Hypertriglyceridaemic waist phenotype is associated with increased severity of coronary artery disease both in type 2 diabetes and nondiabetic patients
VL  - 52
UR  - https://hdl.handle.net/21.15107/rcub_farfar_1257
ER  - 

@conference{
author = "Lalić, K. and Zamaklar, M. and Lalić, N. M. and Ostojić, Miodrag and Kalimanovska, Vesna and Jotić, A. and Rajković, N. and Lukić, L. and Milicić, T. and Singh, Sandra and Stosić, L.",
year = "2009",
publisher = "Springer, New York",
journal = "Diabetologia",
title = "Hypertriglyceridaemic waist phenotype is associated with increased severity of coronary artery disease both in type 2 diabetes and nondiabetic patients",
volume = "52",
url = "https://hdl.handle.net/21.15107/rcub_farfar_1257"
}

Lalić, K., Zamaklar, M., Lalić, N. M., Ostojić, M., Kalimanovska, V., Jotić, A., Rajković, N., Lukić, L., Milicić, T., Singh, S.,& Stosić, L.. (2009). Hypertriglyceridaemic waist phenotype is associated with increased severity of coronary artery disease both in type 2 diabetes and nondiabetic patients. in Diabetologia
Springer, New York., 52.
https://hdl.handle.net/21.15107/rcub_farfar_1257

Lalić K, Zamaklar M, Lalić NM, Ostojić M, Kalimanovska V, Jotić A, Rajković N, Lukić L, Milicić T, Singh S, Stosić L. Hypertriglyceridaemic waist phenotype is associated with increased severity of coronary artery disease both in type 2 diabetes and nondiabetic patients. in Diabetologia. 2009;52.
https://hdl.handle.net/21.15107/rcub_farfar_1257 .

Lalić, K., Zamaklar, M., Lalić, N. M., Ostojić, Miodrag, Kalimanovska, Vesna, Jotić, A., Rajković, N., Lukić, L., Milicić, T., Singh, Sandra, Stosić, L., "Hypertriglyceridaemic waist phenotype is associated with increased severity of coronary artery disease both in type 2 diabetes and nondiabetic patients" in Diabetologia, 52 (2009),
https://hdl.handle.net/21.15107/rcub_farfar_1257 .